Navigation Links
IC Sciences Launches ICS Alliance to Advance Development and Adoption of Informatics Instruments for Next Generation Healthcare
Date:4/2/2008

BOSTON, April 2, 2008 /PRNewswire/ -- IC Sciences Corporation announced today the launch of the company's alliance membership program, ICS Alliance (http://www.icsciencesalliance.com). During the past two years, IC Sciences has been developing components for the newly launched membership program, such as scientific tools, industry products, and market case studies covering healthcare informatics instruments for professional, consumer, and therapeutics medical market sectors. The Alliance program serves as a collaborative nexus of clinicians, healthcare executives, allied professionals, researchers, developers, and other users of these instruments.

Alliance members receive value through a range of program offerings, consisting of a leadership network of experts (Event Series), strategic market analysis and research reports, digital intelligence briefings, and a members-only virtual portal community. Peter M. Nicholas Jr., Founder and Chief Executive Officer of IC Sciences, remarked, "We envision the ICS Alliance as a 'central exchange station' of multi-perspective and multi-sector ideas, tools, practices, and contacts concerning healthcare informatics. We are pleased to be in our second year of the Event Series, which has hosted 18 events and has featured guest hosts such as Clayton Christensen of Harvard Business School, Jonathan Bush of AthenaHealth, and Charlie Baker of Harvard Pilgrim Health. We look forward to inviting the nation's e-health executives, clinicians, and medical informatics leaders to join our membership in 2008 and beyond."

Alliance members, who currently include Revolution Health, AthenaHealth, PatientsLikeMe, and Blue Cross Blue Shield of Massachusetts, joined the program because of a collective interest in understanding this rapidly evolving field, as well as how new sciences and technologies are improving the effectiveness, value, and experience of healthcare. These informatics instruments are used by clinicians, patients, consumers, payers, and therapeutics manufacturers in myriad contexts and applications, including patient engagement, collective intelligence among clinician or patient peers, clinical performance management, and therapeutic product support.

To learn more about ICS Alliance and membership benefits and opportunities, visit http://www.icsciencesalliance.com.

About IC Sciences Corporation

IC Sciences Corporation is a closely held, private organization pioneering in the medical information sciences and informed clinical technology markets. IC Sciences Corporation, through its operating companies, is creating the world's most comprehensive and broadly based developer of intelligent informatics systems and digital informatics instruments for the professional, consumer, and therapeutics medical markets. Our core business is about employing the Internet and related technology platforms to support the delivery of informed clinical systems that optimally impact patient care through the science and the art of contextually differentiated informing. For more information, please visit: http://www.ICSciences.com

Contact:

IC Sciences Corporation

One Joy Street Boston, MA 02108

publicrelations@icsciences.com

1-800-603-1420


'/>"/>
SOURCE IC Sciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company ... better treatment for triple negative breast cancer (TNBC), announced today ... program. The YEi Start in ... help entrepreneurs grow their business in France ... companies selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
(Date:2/16/2017)... 16, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, today announced it ... and entered into a $5 million credit facility ... use the capital for general corporate purposes to ... the treatment of serious diseases treated by dermatologists. ...
Breaking Biology Technology:
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/24/2017)... Biopharm Reports has carried out a ... nuclear magnetic resonance spectroscopy (NMR). This involved the ... practices, developments, trends and end-user plans over the ... opportunities. These areas include growth in the use ... innovation requirements, hyphenated NMR techniques, main suppliers of ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017 ... enhancing user experience and security for consumer electronics, ... next-generation payment processing systems and cybersecurity solutions, today ... banks, enterprises and financial institutions worldwide to bolster ... of the end-to-end secure user authentication platforms they ...
Breaking Biology News(10 mins):